Literature DB >> 8755642

Inflammatory and hyperproliferative skin disease in mice that express elevated levels of the IL-1 receptor (type I) on epidermal keratinocytes. Evidence that IL-1-inducible secondary cytokines produced by keratinocytes in vivo can cause skin disease.

R W Groves1, T Rauschmayr, K Nakamura, S Sarkar, I R Williams, T S Kupper.   

Abstract

Interleukin (IL)-1 induces a cascade of secondary cytokines in a large number of cell types in vitro, including monocytes, fibroblasts, synovial cells, and keratinocytes. Although it has been proposed that autocrine or paracrine activation of such cells by IL- 1 in situ could orchestrate a local inflammatory response, formal proof for such an hypothesis has been lacking. In an attempt to lower the threshold for secondary cytokine production in these cells in response to IL-1, we have generated transgenic mice (designated IR10) which overexpress functional type 1 IL-1 receptor in basal layer of epidermis keratinocytes. As predicted, keratinocytes from these animals were substantially more responsive to exogenous IL-1 than nontransgenic keratinocytes when stimulated in vitro. When challenged with known inducers of keratinocyte IL-1 synthesis and release, skin of IR10 mice exhibited an exaggerated inflammatory response, characterized by epidermal hyperplasia and an acute dermal inflammatory cell infiltrate. In this setting, the secondary epidermal cytokines gro-alpha and GM-CSF were strongly induced in transgenic epidermis but not in control skin. To confirm that these changes were indeed related to IL-1 mediated activation pathways, IR10 mice were crossed to a distinct line of transgenic mice that overexpress 17-kD IL-l alpha in basal keratinocytes. Double transgenic mice derived from this cross breeding experiment developed spontaneous inflammation of the skin, similar in appearance to that induced by PMA, both histologically and macroscopically, and distinct from that seen in either parental strain spontaneously. Furthermore, secondary cytokines were more strongly induced in the double transgenic than in either parental strain. These findings conclusively demonstrate the potential for functional autocrine pathways of keratinocyte activation mediated by IL-1 alpha in vivo, and suggest that level of expression of type 1 IL-1 receptor may function as a significant control point in physiologic IL-1 mediated autocrine pathways.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8755642      PMCID: PMC507435          DOI: 10.1172/JCI118797

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

Review 1.  Autocrine secretion--10 years later.

Authors:  M B Sporn; A B Roberts
Journal:  Ann Intern Med       Date:  1992-09-01       Impact factor: 25.391

2.  Identification of the promoter region of human interleukin 1 type I receptor gene: multiple initiation sites, high G+C content, and constitutive expression.

Authors:  K Ye; C A Dinarello; B D Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

3.  Interleukin-1 receptor antagonist in normal and psoriatic epidermis.

Authors:  C Hammerberg; W P Arend; G J Fisher; L S Chan; A E Berger; J S Haskill; J J Voorhees; K D Cooper
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

4.  Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4.

Authors:  F Colotta; F Re; M Muzio; R Bertini; N Polentarutti; M Sironi; J G Giri; S K Dower; J E Sims; A Mantovani
Journal:  Science       Date:  1993-07-23       Impact factor: 47.728

5.  Interleukin-1 alpha gene expression and localization of interleukin-1 alpha protein during tumor promotion.

Authors:  T M Oberyszyn; C L Sabourin; G N Bijur; A S Oberyszyn; L G Boros; F M Robertson
Journal:  Mol Carcinog       Date:  1993       Impact factor: 4.784

6.  Interleukin-1 alpha mediates phorbol ester-induced inflammation and epidermal hyperplasia.

Authors:  W Y Lee; M F Lockniskar; S M Fischer
Journal:  FASEB J       Date:  1994-10       Impact factor: 5.191

7.  Immunohistochemical localization of the interleukin-1 system in the mouse ovary during follicular growth, ovulation, and luteinization.

Authors:  C Simón; A Frances; G Piquette; M L Polan
Journal:  Biol Reprod       Date:  1994-02       Impact factor: 4.285

8.  Distribution of interleukin 1 receptor antagonist protein (IRAP), interleukin 1 receptor, and interleukin 1 alpha in normal and psoriatic skin. Decreased expression of IRAP in psoriatic lesional epidermis.

Authors:  M Kristensen; B Deleuran; D J Eedy; M Feldmann; S M Breathnach; F M Brennan
Journal:  Br J Dermatol       Date:  1992-10       Impact factor: 9.302

9.  Epidermal expression of intercellular adhesion molecule 1 is not a primary inducer of cutaneous inflammation in transgenic mice.

Authors:  I R Williams; T S Kupper
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

10.  The type II "receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor.

Authors:  F Re; M Muzio; M De Rossi; N Polentarutti; J G Giri; A Mantovani; F Colotta
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more
  19 in total

1.  Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice.

Authors:  N L Ward; C M Loyd; J A Wolfram; D Diaconu; C M Michaels; T S McCormick
Journal:  Br J Dermatol       Date:  2011-04       Impact factor: 9.302

2.  Interleukin-1alpha and interleukin-6 enhance the antibacterial properties of cultured composite keratinocyte grafts.

Authors:  Gulsun Erdag; Jeffrey R Morgan
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

Review 3.  [Beyond immunopathogenesis. Insulin resistance and "epidermal dysfunction"].

Authors:  W-H Boehncke; S Boehncke; C Buerger
Journal:  Hautarzt       Date:  2012-03       Impact factor: 0.751

4.  IL-1α modulates neutrophil recruitment in chronic inflammation induced by hydrocarbon oil.

Authors:  Pui Y Lee; Yutaro Kumagai; Yuan Xu; Yi Li; Tolga Barker; Chao Liu; Eric S Sobel; Osamu Takeuchi; Shizuo Akira; Minoru Satoh; Westley H Reeves
Journal:  J Immunol       Date:  2010-12-29       Impact factor: 5.422

Review 5.  Inflammation and skeletal metastasis.

Authors:  Hernan Roca; Laurie K McCauley
Journal:  Bonekey Rep       Date:  2015-06-10

6.  Keratinocyte expression of the type 2 interleukin 1 receptor mediates local and specific inhibition of interleukin 1-mediated inflammation.

Authors:  T Rauschmayr; R W Groves; T S Kupper
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

7.  Topical application of delphinidin reduces psoriasiform lesions in the flaky skin mouse model by inducing epidermal differentiation and inhibiting inflammation.

Authors:  H C Pal; J C Chamcheu; V M Adhami; G S Wood; C A Elmets; H Mukhtar; F Afaq
Journal:  Br J Dermatol       Date:  2014-12-23       Impact factor: 9.302

8.  Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype.

Authors:  P W Cook; M Piepkorn; C H Clegg; G D Plowman; J M DeMay; J R Brown; M R Pittelkow
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

9.  IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation.

Authors:  Hak-Ling Ma; Spencer Liang; Jing Li; Lee Napierata; Tom Brown; Stephen Benoit; Mayra Senices; Davinder Gill; Kyriaki Dunussi-Joannopoulos; Mary Collins; Cheryl Nickerson-Nutter; Lynette A Fouser; Deborah A Young
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

10.  Overexpression of IL-1alpha in skin differentially modulates the immune response to scarification with vaccinia virus.

Authors:  Tian Tian; Luzheng Liu; Eva-Jasmin Freyschmidt; George F Murphy; Thomas S Kupper; Robert C Fuhlbrigge
Journal:  J Invest Dermatol       Date:  2008-07-10       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.